The inclusion of more patients with IDH1/2 and ATRX mutations in the low-risk group and more patients with EGFR mutations in the high-risk group indicates that BM-gene-related risk scores can distinguish glioma patients with different prognoses. This evidence concerns the gene EGFR and central nervous system cancer.